Phase 3
Completed N=15
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
FSGS
Source: ClinicalTrials.gov NCT02683889 ↗
Enrolled (actual)
15
Serious AEs
6.7%
Results posted
Mar 2026
Primary outcomePrimary: Rate of Recurrence of FSGS as Seen in Renal Transplant Biopsies Proteinuria — 14 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate of Recurrence of FSGS as Seen in Renal Transplant Biopsies Proteinuria |
14 | — |
| PRIMARY Rate of Recurrence of Proteinuria |
3 | — |
| SECONDARY Renal Function After Transplantation |
— | — |
Eligibility Criteria
Inclusion Criteria
- FSGS
- To receive either a live donor or deceased donor kidney transplant
Exclusion Criteria
- Not having FSGS
Data sourced from ClinicalTrials.gov (NCT02683889). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.